Divi’s Laboratories Limited announced its consolidated unaudited financial results for the quarter ended 30 September 2025, showcasing a healthy performance both in revenue and profitability compared to the same quarter last year.
For Q2 FY2025, the company reported a revenue from operations of ₹2,715 crore, marking a 15.9% increase from ₹2,338 crore recorded in Q2 FY2024. The growth was driven by improved exports and steady demand in the custom synthesis segment.
The total income for the quarter rose to ₹2,860 crore, up 17% YoY from ₹2,444 crore in the corresponding quarter of the previous year.
Operating performance remained solid with EBITDA rising 24% year-on-year to ₹888 crore against ₹716 crore in the corresponding quarter of the previous year. The EBITDA margin improved to 32.7% from 30.6%.
The profit before tax (PBT) came in at ₹912 crore, up 26.3% YoY from ₹722 crore in Q2 FY2024. After accounting for taxes of ₹223 crore, the net profit stood at ₹689 crore, a sharp 35.1% jump YoY over ₹510 crore in the same quarter last year.
